NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment

Why does this matter? NEREUS™ provides a new option for those who have struggled with motion sickness, potentially improving travel experiences and overall quality of life. The direct-to-consumer platform also increases accessibility to the medication.

Motion sickness occurs when the brain receives conflicting signals from the eyes, inner ear, and body during motion. This sensory mismatch triggers the release of substance P, activating NK-1 receptors in the central nervous system, leading to nausea and vomiting. NEREUS™ works by blocking these receptors, interrupting this pathway.

The FDA approved NEREUS™ on December 30, 2025, based on two Phase 3 clinical trials (Motion Syros and Motion Serifos) conducted under real-world sea travel conditions. These studies demonstrated that NEREUS™ significantly prevented vomiting compared to a placebo.

However, it's important to note that NEREUS™ may impair abilities required for driving or operating heavy machinery and is not recommended for patients with liver or severe kidney problems. The most common side effects include drowsiness, headache, and fatigue. These factors should be carefully considered when choosing a motion sickness treatment.

Vanda Pharmaceuticals' commercial strategy involves a significant price spread between its direct-to-consumer portal and traditional pharmacies, incentivizing patients to bypass insurance and purchase directly from nereus.us&ref=yanuki.com.

NEREUS™ blocks NK-1 receptors in the brain, interrupting the vomiting pathway triggered by motion sickness.

The most common side effects include drowsiness, headache, and fatigue.

NEREUS™ is available by prescription through retail pharmacies nationwide and directly through nereus.us&ref=yanuki.com.

What are your experiences with motion sickness treatments? Do you think NEREUS™ will be a game-changer? Share this article with others who need to stay ahead of this trend!